{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:05:12Z","timestamp":1791615912961,"version":"4.3.4"},"reference-count":119,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diagnosing and managing metabolic dysfunction-associated steatotic liver disease (MASLD) remains a major challenge in primary care due to lack of agreement on diagnostic tools, difficulty in identifying symptoms and determining their cause, absence of approved pharmacological treatments, and limited awareness of the disease. However, prompt diagnosis and management are critical to preventing MASLD from progressing to more severe forms of liver disease. This highlights the need to raise awareness and improve understanding of MASLD among both patients and physicians. The patient perspective is invaluable to advancing our knowledge of this disease and how to manage it, as their perspectives have led to the growing recognition that patients experience subtle symptoms and that patient-reported outcomes should be incorporated into drug development. This review and expert opinion examine MASLD and metabolic dysfunction-associated steatohepatitis from the patient and physician perspective from pre-diagnosis to diagnosis and early care, through to progression to advanced liver damage. Specifically, the paper dives into the issues patients and physicians experience, and, in turn, what is required to improve diagnosis and management, including tips and tools to empower patients and physicians dealing with MASLD.<\/jats:p>","DOI":"10.3390\/jcm12196216","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:58:17Z","timestamp":1695718697000},"page":"6216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective"],"prefix":"10.3390","volume":"12","author":[{"given":"Wayne","family":"Eskridge","sequence":"first","affiliation":[{"name":"Fatty Liver Foundation, Boise, ID 83706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-7843","authenticated-orcid":false,"given":"Donna R.","family":"Cryer","sequence":"additional","affiliation":[{"name":"Global Liver Institute, Washington, DC 20016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Metabolic Liver Research Program, Department of Medicine, University Medical Center of the Johannes Gutenberg University, 155131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1651","authenticated-orcid":false,"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[{"name":"Cardiometabolic Risk Laboratory, Institute of Clinical Physiology, Italian National Research Council CNR, 00133 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmeet","family":"Malhi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina M.","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN 55901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Fatty Liver Program, Karsh Division of Gastroenterology and Hepatology, Cedar Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, VCU School of Medicine and Health System and Division of Gastroenterology, Department of Internal Medicine, VCU School of Medicine, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep4.1599","article-title":"The growing burden of disability related to nonalcoholic fatty liver disease: Data From the Global Burden of Disease 2007\u20132017","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1665-2681(19)31317-1","article-title":"Primary care practitioners survey of non-alcoholic fatty liver disease","volume":"12","author":"Said","year":"2013","journal-title":"Ann. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2021). EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: The impact on patient-reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.clinthera.2021.01.021","article-title":"Therapy for nonalcoholic fatty liver disease: Current options and future directions","volume":"43","author":"Campbell","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2011.03.020","article-title":"Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort","volume":"56","author":"Armstrong","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_9","first-page":"641","article-title":"Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis","volume":"7","author":"Nagra","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alexander, M., Loomis, A.K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., and Rijnbeek, P. (2018). Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med., 16.","DOI":"10.1186\/s12916-018-1103-x"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ajg.2014.134","article-title":"Nonalcoholic fatty liver disease is underrecognized in the primary care setting","volume":"110","author":"Blais","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/imj.13667","article-title":"Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: Limited awareness of surrogate markers of fibrosis","volume":"48","author":"Patel","year":"2018","journal-title":"Intern. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12325-018-0856-0","article-title":"Understanding patient preferences and unmet needs in non-alcoholic steatohepatitis (NASH): Insights from a qualitative online bulletin board study","volume":"36","author":"Cook","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","article-title":"Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): Results of a qualitative study","volume":"14","author":"Doward","year":"2021","journal-title":"Patient"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: A systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q.M., and Hanratty, B. (2020). Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003100"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13597","DOI":"10.1111\/eci.13597","article-title":"Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver","volume":"51","author":"Shanmugam","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e000638","DOI":"10.1136\/bmjgast-2021-000638","article-title":"Uncovering undiagnosed liver disease: Prevalence and opportunity for intervention in a population attending colonoscopy","volume":"8","author":"Koo","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: A real world analysis of Medicare data","volume":"51","author":"Loomba","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep4.1935","article-title":"Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning","volume":"6","author":"Noureddin","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Eskridge, W., Vierling, J.M., Gosbee, W., Wan, G.A., Hyunh, M.L., and Chang, H.E. (2021). Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260320"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep4.1899","article-title":"Prevalence and risk factors of advanced liver fibrosis in a population-based study in Germany","volume":"6","author":"Huber","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fmed.2014.00004","article-title":"Knowing what\u2019s out there: Awareness of non-alcoholic fatty liver disease","volume":"1","author":"Ghevariya","year":"2014","journal-title":"Front. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1440-1746.2009.05914.x","article-title":"Non-alcoholic fatty liver disease: An expanding problem with low levels of awareness in Hong Kong","volume":"24","author":"Leung","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alemany-Pages, M., Moura-Ramos, M., Araujo, S., Macedo, M.P., Ribeiro, R.T., do \u00d3, D., Ramalho-Santos, J., and Azul, A.M. (2020). Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: Time to go public with insulin resistance?. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-09249-5"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/gastro\/gov047","article-title":"Perceptions of non-alcoholic fatty liver disease\u2014An Asian community-based study","volume":"4","author":"Goh","year":"2016","journal-title":"Gastroenterol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/MCG.0000000000000075","article-title":"Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk","volume":"49","author":"Wieland","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: A patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs\u2019 experiences and perceptions of early detection of liver disease: A qualitative study in primary care","volume":"68","author":"Standing","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e3452","DOI":"10.1002\/dmrr.3452","article-title":"Advanced liver fibrosis and the metabolic syndrome in a primary care setting","volume":"37","author":"Schreiner","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101848","DOI":"10.1016\/j.clinre.2021.101848","article-title":"Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners","volume":"46","author":"Canivet","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed","year":"2015","journal-title":"World. J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cld.2015.10.006","article-title":"Clinical presentation and patient evaluation in nonalcoholic fatty liver disease","volume":"20","author":"Patel","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.28376","article-title":"Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011)","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s42000-018-0049-x","article-title":"Sarcopenic obesity","volume":"17","author":"Polyzos","year":"2018","journal-title":"Hormones"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.2007.139303","article-title":"Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance","volume":"57","author":"Newton","year":"2008","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/jgh.15172","article-title":"Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"36","author":"Yamamura","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12955-021-01778-w","article-title":"Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: A national multicenter survey","volume":"19","author":"Huang","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fmed.2019.00061","article-title":"The patient perspectives on future therapeutic options in NASH and patient needs","volume":"6","author":"Cook","year":"2019","journal-title":"Front. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","article-title":"The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study","volume":"1","author":"Balp","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.aohep.2020.10.005","article-title":"Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience","volume":"22","author":"Stepanova","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijscr.2020.01.028","article-title":"An obese patient with acute cholecystitis, nonalcoholic steatohepatitis and cirrhosis: A case report","volume":"67","author":"Zuiki","year":"2020","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1148\/rg.2018170149","article-title":"US of right upper quadrant pain in the emergency department: Diagnosing beyond gallbladder and biliary disease","volume":"38","author":"Joshi","year":"2018","journal-title":"Radiographics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.4254\/wjh.v13.i12.1816","article-title":"Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?","volume":"13","author":"Purssell","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e000106","DOI":"10.1136\/bmjgast-2016-000106","article-title":"Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease","volume":"3","author":"Sayiner","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"David","year":"2009","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL)","volume":"14","author":"Golabi","year":"2016","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/apt.12038","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: A population-based study","volume":"36","author":"Gerber","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_63","unstructured":"(2022, September 14). NASH Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting Final Report. Available online: https:\/\/globalliver.org\/wp-content\/uploads\/2022\/07\/FINAL_NASH_EL_PFDD_REPORT.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.jhepr.2020.100099","article-title":"Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis","volume":"2","author":"McSweeney","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1007\/s10620-016-4124-3","article-title":"Portal hypertension complications are frequently the first presentation of NAFLD in patients undergoing liver transplantation evaluation","volume":"61","author":"Nagpal","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpsychores.2018.07.004","article-title":"Quality of life in patients with nonalcoholic fatty liver disease: A systematic review","volume":"112","author":"Assimakopoulos","year":"2018","journal-title":"J. Psychosom. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 1: Definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2022). 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes\u20142022. Diabetes Care, 45, S46\u2013S59.","DOI":"10.2337\/dc22-S004"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_71","unstructured":"(2022, September 14). Non-Alcoholic Fatty Liver Disease (NAFLD): Assessment and Management. Available online: https:\/\/www.nice.org.uk\/guidance\/ng49\/chapter\/Recommendations."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: Real-world data from a large U.S. claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.cgh.2017.06.011","article-title":"Lifestyle behavior change in patients with nonalcoholic fatty liver disease: A qualitative study of clinical practice","volume":"15","author":"Avery","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"716783","DOI":"10.3389\/fnut.2021.716783","article-title":"Dietary interventions in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"8","author":"Houttu","year":"2021","journal-title":"Front. Nutr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2016.04.036","article-title":"Exercise-based interventions for nonalcoholic fatty liver disease: A meta-analysis and meta-regression","volume":"14","author":"Orci","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: Implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2020","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., Romero, D., Abdelmalek, M.F., Anstee, Q.M., and Arab, J.P. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol., 101133.","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"585425","DOI":"10.3389\/fmed.2020.585425","article-title":"Psychological biomarkers and fibrosis: An innovative approach to non-alcoholic fatty liver disease","volume":"7","year":"2020","journal-title":"Front. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/oby.2010.254","article-title":"Cognitive-behavioral treatment of nonalcoholic fatty liver disease: A propensity score-adjusted observational study","volume":"19","author":"Moscatiello","year":"2011","journal-title":"Obesity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2018.07.013","article-title":"An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers","volume":"69","author":"Mazzotti","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Polanco-Briceno, S., Glass, D., Stuntz, M., and Caze, A. (2016). Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res. Notes, 9.","DOI":"10.1186\/s13104-016-1946-1"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"17562848211042200","DOI":"10.1177\/17562848211042200","article-title":"Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: A nationwide survey","volume":"14","author":"Saeed","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_87","first-page":"651","article-title":"Nonalcoholic fatty liver hepatitis and fatty cirrhosis mimicking alcoholic liver diseases","volume":"21","author":"Spech","year":"1983","journal-title":"Z. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-5926-4-10","article-title":"The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis","volume":"4","author":"Poynard","year":"2005","journal-title":"Comp. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ratziu, V., Massard, J., Charlotte, F., Messous, D., Imbert-Bismut, F., Bonyhay, L., Tahiri, M., Munteanu, M., Thabut, D., and Cadranel, J.F. (2006). Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-6"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hepr.13688","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"51","author":"Tokushige","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_91","first-page":"S39","article-title":"Weight loss as a treatment for nonalcoholic fatty liver disease","volume":"40","author":"Clark","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review","volume":"22","author":"Golabi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Babu, A.F., Csader, S., Lok, J., G\u00f3mez-Gallego, C., Hanhineva, K., El-Nezami, H., and Schwab, U. (2021). Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: A systematic review and meta-analysis. Nutrients, 13.","DOI":"10.3390\/nu13093135"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2036.2009.04122.x","article-title":"Clinical trial: A nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease","volume":"30","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of \u226510 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Reginato, E., Pippi, R., Aiello, C., Sbroma Tomaro, E., Ranucci, C., Buratta, L., Bini, V., Marchesini, G., De Feo, P., and Fanelli, C. (2019). Effect of short term intensive lifestyle intervention on hepatic steatosis indexes in adults with obesity and\/or type 2 diabetes. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060851"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1097\/MD.0000000000002159","article-title":"Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: A population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"56","DOI":"10.12688\/f1000research.21918.1","article-title":"Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis","volume":"9","year":"2020","journal-title":"F1000Res"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","article-title":"NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients","volume":"19","author":"Treeprasertsuk","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s11695-015-1691-x","article-title":"Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology","volume":"25","author":"Bower","year":"2015","journal-title":"Obes. Surg."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.gastro.2009.04.052","article-title":"Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease","volume":"137","author":"Mathurin","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2014.10.029","article-title":"Inflammation, psychiatric symptoms, and opioid use are associated with pain and disability in patients with cirrhosis","volume":"13","author":"Rogal","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_113","unstructured":"(2022, September 14). FibroScan for Assessing Liver Fibrosis and Cirrhosis in Primary Care. Available online: https:\/\/www.nice.org.uk\/advice\/mib216\/chapter\/Expert-comments."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jada.2008.11.041","article-title":"Position of the American Dietetic Association: Weight management","volume":"109","author":"Seagle","year":"2009","journal-title":"J. Am. Diet Assoc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/2150131917715336","article-title":"Provider advice about weight loss in a primary care sample of obese and overweight patients","volume":"8","author":"Halbert","year":"2017","journal-title":"J. Prim. Care Community Health"},{"key":"ref_117","unstructured":"(2022, September 14). Non-Alcoholic Fatty Liver Disease (NAFLD). Available online: https:\/\/litmus-project.eu\/non-alcoholic-fatty-liver-disease-nafld\/."},{"key":"ref_118","unstructured":"(2022, September 14). Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE). Available online: https:\/\/fnih.org\/our-programs\/biomarkers-consortium\/programs\/nimble."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:58:48Z","timestamp":1760129928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":119,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12196216"],"URL":"https:\/\/doi.org\/10.3390\/jcm12196216","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}